论文信息 - The Discovery and Development of SU14813, a Next-Generation Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Human Malignancies

The Discovery and Development of SU14813, a Next-Generation Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Human Malignancies

Commentary on: [Shem Patyna, A. Douglas Laird, Dirk B. Mendel, Anne-Marie O'Farrell, Chris Liang, Huiping Guan, Tomas Vojkovsky, Stefan Vasile, Xueyan Wang, Jeffrey Chen, Maren Grazzini, Cheng Y. Yang, Joshua O. Haznedar, Juthamas Sukbuntherng, Wei-Zhu Zhong, Julie M. Cherrington, and Dana Hu-

D. Hu-Lowe | N. Brega | S. Patyna

[1] J. Verweij,et al. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. , 2011, European journal of cancer.

[2] C. Liang,et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity , 2006, Molecular Cancer Therapeutics.

[3] G. Giaccone,et al. Phase I trial of SU14813 in patients with advanced solid malignancies. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.